PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.10
Ask: 3.40
Change: -0.10 (-2.99%)
Spread: 0.30 (9.677%)
Open: 3.35
High: 3.35
Low: 3.25
Prev. Close: 3.35
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS SUMMARY: New MySale Chairman Buys 60,000 Shares

Mon, 27th Jul 2015 16:24

LONDON (Alliance News) - The following is a summary of director dealings reported in London on Monday.
----------
MySale Group said its newly appointed Chairman Iain McDonald bought 60,000 shares at a price of 44.91483 pence per share Monday.

After the purchase he holds 148,482 shares, representing approximately 0.10% of the issued share capital.

The online flash sale retailer earlier Monday said it is set to post higher revenue for the year to the end of June and said its performance improved in the second half. MySale said its revenue for the year was up by 5% to AUD235 million and said its second-half underlying earnings before interest, taxation, depreciation and amortisation should be broadly break-even.

In addition to the trading update, the company said it had appointed McDonald as its new non-executive chairman. He is a partner at William Currie Group, the technology and e-commerce investment company.

"MySale is focussed on profitable growth and we are pleased with the progress achieved over the last six months. We are delighted that Iain McDonald has joined as chairman bringing a wealth of online retail and significant UK capital markets experience," said Carl Jackson, MySale's chief executive.

The stock closed up 10% at 43.96p on Monday, having hit a high for the year of 46.00p earlier in the day.
----------
Range Resources said it has been informed that all of the necessary government and regulatory approvals have been received which will allow the company to secure its funding package from Beijing Sibo Investment Management.

The last hurdle is gaining approval from Range shareholders at the extraordinary general meeting which will be held in August, with a firm date to be declared before the end of July. Shareholders will also vote on a related subscription by the directors of the company.

In early June, Range received the first tranche of funding, totalling GBP5.2 million, resulting in Range issuing 650 million new shares to Beijing Sibo at the subscription price of GBP0.008 per share, giving it an 11.5% stake in Range. Shareholder approval was not needed for that first tranche. Under the second tranche, Sibo will subscribe to further shares at the same price as the first tranche, to total a USD22.1 million investment. However the company said the final amount will be confirmed after the EGM.

Following the second tranche, Range will have secured USD30 million from the deal, with a further USD300,000 set to be received from its directors who have agreed to subscribe to shares at the same subscription price.

The directors investing are Chairman David Chen who is investing USD96,000, Executive Director Yan Liu with USD76,000 and Non Executive Directors Zhiwei Gu and Juan Wang who will invest USD25,000 each.

Shares closed down 0.3% at 0.623p Monday.
----------
Allergy Therapeutics said Chief Executive Officer Manuel Llobet bought 50,000 shares at a price of 24.45 pence per share Friday. Following this transaction, Llobet's beneficial holding now stands at 3.2 million shares, which represents 0.58% of the issued share capital. The purchase came after Allergy Therapeutics on Thursday said it expects to post revenue growth of 11% for its recently ended financial year at constant currency, although its reported figures will be hit the weakening of the euro. Shares in the research and development company closed up 3.3% at 25.5p Monday.
----------
Unilever said Chief Marketing and Communication Officer Keith Weed sold 2,650 shares at a price of 2,899.9671 pence per share Monday. A person connected to Weed, Catherine Weed, also sold 3,700 share in the company at a price of 2,903.77 pence last Friday. Shares in the company closed down 1.4% at 2,858.81 pence Monday.
----------
Publishing Technology said Chief Executive Officer Michael Cairns bought 65,000 shares at a price of 133 pence per share on Friday. Cairns' beneficial interest in the company now is 95,400 shares, representing approximately 0.58% of its issued share capital. Shares in the content solutions provider closed down 0.6% at 126.75p Monday.
----------
Lowland Investment Co said Non-Executive Director Kevin Carter bought 3,000 shares at a price of 1,373.60 pence per share on Monday. Following this transaction, Carter holds 8,000 shares, which represents 0.02% stake in the trust. The stock closed down 0.8% at 1,370.50p Monday.
----------
Murray International said Chairman of the Board of the Manager Kevin Carter bought 5,000 shares at a price of 900.46 pence per share on Monday. Following this transaction, Carter holds 30,000 shares, which represents a 0.02% stake in the trust. The stock closed down 0.2% at 902.00p Monday.
----------
JPMorgan Emerging Markets Investment Trust said Non-Executive Director Andrew Page bought 5,000 shares at a price of 578.37 pence per share Monday. The purchase is his only holding in the company after being appointed in December 2014. The stock closed down 1.7% at 573.50p Monday.
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
26 Oct 2020 14:17

IN BRIEF: Allergy Therapeutics Kicks Off Grass Allergy Therapy Study

IN BRIEF: Allergy Therapeutics Kicks Off Grass Allergy Therapy Study

Read more
26 Oct 2020 13:37

Allergy Therapeutics screens first patients in grass pollen study

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the screening of the first patient in its exploratory field study 'G309', to evaluate the efficacy and safety of 'Grass MATA MPL' in subjects with seasonal allergic rhinitis or rhinoconjunctivitis induced by grass pollen exposure.

Read more
23 Sep 2020 14:02

UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost

UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost

Read more
4 Sep 2020 19:39

IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform

IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform

Read more
3 Sep 2020 15:31

Allergy Therapeutics signs new vaccine deal with Saliba and DeepVax

(Sharecast News) - Biotechnology company Allergy Therapeutics announced further investment in virus-like particle (VLP) technology for applications beyond the allergy immunotherapy field on Thursday.

Read more
15 Jul 2020 11:47

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

Read more
15 Jul 2020 09:03

Allergy Therapeutics revenues grow despite Covid-19 disruption

(Sharecast News) - Biotechnology company Allergy Therapeutics reported a "strong" full-year performance on Wednesday despite challenges stemming from the Covid-19 pandemic.

Read more
9 Jul 2020 21:19

IN BRIEF: Allergy Therapeutics To Recommence Birch B301 Trial

IN BRIEF: Allergy Therapeutics To Recommence Birch B301 Trial

Read more
9 Jul 2020 16:26

Allergy Therapeutics pleased with invalidation of B301 trial data

(Sharecast News) - Biotechnology company Allergy Therapeutics announced the outcome of scientific advice from the German Regulatory Authority, the Paul Ehrlich Institute (PEI), over invalidation of the primary endpoint data of the Birch MATA MPL pivotal phase 3 clinical trial, or 'B301', on Thursday.

Read more
24 Jun 2020 11:53

Allergy Therapeutics Anticipates Profit Ahead Of Expectations

Allergy Therapeutics Anticipates Profit Ahead Of Expectations

Read more
24 Jun 2020 10:12

Allergy Therapeutics on track to 'significantly' exceed FY expectations

(Sharecast News) - Biotechnology company Allergy Therapeutics said on Wednesday that its 2020 trading performance was on track to exceed market expectations.

Read more
4 Mar 2020 10:46

Allergy Therapeutics Well-Placed Despite Regulatory "Challenge"

Allergy Therapeutics Well-Placed Despite Regulatory "Challenge"

Read more
26 Feb 2020 16:15

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
16 Jan 2020 13:28

Allergy Therapeutics Outlook Confident As Revenue Rises In First Half

Allergy Therapeutics Outlook Confident As Revenue Rises In First Half

Read more
26 Nov 2019 14:15

Allergy Therapeutics to take 'stepwise approach' to upcoming grass study

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics updated the market on its grass MATA MPL phase 3 study, due to start in autumn 2020, on Tuesday, reporting that following further investigation of the phase 3 birch MATA MPL study, the upcoming grass study would now take a 'stepwise approach'.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.